CDK4 and diabetes mellitus: Although no previous clinical trials on CDKi have focused on the role of diabetes, in vivo studies have shown that genetic CDK4 loss as well as treatment with the CDKi Palbociclib lead to the reduction in beta-islet pancreatic cells.